Emmanuelle di Tomaso
Overview
Explore the profile of Emmanuelle di Tomaso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
6979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2020 Apr;
11(14):1289.
PMID: 32292577
[This corrects the article DOI: 10.18632/oncotarget.26215.].
2.
Hu S, Marineau J, Rajagopal N, Hamman K, Choi Y, Schmidt D, et al.
Cancer Res
. 2019 May;
79(13):3479-3491.
PMID: 31064851
Recent studies suggest that targeting transcriptional machinery can lead to potent and selective anticancer effects in cancers dependent on high and constant expression of certain transcription factors for growth and...
3.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2018 Nov;
9(81):35226-35240.
PMID: 30443290
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone...
4.
McKeown M, Johannessen L, Lee E, Fiore C, Tomaso E
Haematologica
. 2018 Oct;
104(4):e138-e142.
PMID: 30337363
No abstract available.
5.
Baselga J, Im S, Iwata H, Cortes J, De Laurentiis M, Jiang Z, et al.
Lancet Oncol
. 2017 Jun;
18(7):904-916.
PMID: 28576675
Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant...
6.
Massacesi C, Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al.
Onco Targets Ther
. 2016 Jan;
9:203-10.
PMID: 26793003
The PI3K-AKT-mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may...
7.
Vansteenkiste J, Canon J, De Braud F, Grossi F, De Pas T, Gray J, et al.
J Thorac Oncol
. 2015 Jun;
10(9):1319-1327.
PMID: 26098748
Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was...
8.
OBrien N, McDonald K, Tong L, Von Euw E, Kalous O, Conklin D, et al.
Clin Cancer Res
. 2014 Jun;
20(13):3507-20.
PMID: 24879796
Purpose: Altered PI3K/mTOR signaling is implicated in the pathogenesis of a number of breast cancers, including those resistant to hormonal and HER2-targeted therapies. Experimental Design: The activity of four classes...
9.
Rodon J, Brana I, Siu L, de Jonge M, Homji N, Mills D, et al.
Invest New Drugs
. 2014 Mar;
32(4):670-81.
PMID: 24652201
Purpose: The pan-Class I PI3K inhibitor buparlisib (BKM120) has shown activity in a range of preclinical cancer models. This first-in-man study was initiated to identify the maximum tolerated dose (MTD)...
10.
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al.
Clin Cancer Res
. 2014 Jan;
20(7):1935-45.
PMID: 24470511
Purpose: Phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway activation in patients with HER2-positive (HER2(+)) breast cancer has been implicated in de novo and acquired trastuzumab resistance. The purpose of this study was to...